Bayer's Adempas Patent Cliff Meets a Market That Won't Reward Good News
Published on 10/09/2026 at 03:50 | Editorial boerse-global.de
Bayer shares came under pressure across two consecutive sessions this week, with the stock surrendering 2.1% to close at EUR 42.95 before sliding a further 3.0% to EUR 42.56. The declines had nothing to do with company-specific setbacks. Rising bond yields, firmer oil prices and renewed inflation jitters combined with geopolitical tensions in the Middle East to sap risk appetite across European equity markets, dragging the DAX lower and pulling Bayer along with it. The latest move pushed the stock just beneath its 200-day moving average of EUR 43.22, a level that now serves as the immediate battleground for chart watchers.
What makes the timing awkward is that Bayer has been quietly stacking up operational wins. The US Food and Drug Administration has accepted an expanded application for finerenone in adults with chronic kidney disease, a filing built on data from the Phase III FIND-CKD trial. That regulatory green light for review — covering the drug marketed as Kerendia — represents exactly the kind of pipeline milestone the Leverkusen-based group needs as it works to offset revenue that will eventually fall away.
Generics Arrive for a Key Heart Drug
Not all of the portfolio news is favorable, however. Zydus Lifesciences and MSN Laboratories have both announced the US launch of the first generic version of Adempas, Bayer's riociguat-based cardiovascular treatment. The arrival of copycat rivals on American soil ratchets up competitive pressure on a product that has contributed meaningfully to the company's pharmaceutical revenue.
Bayer is simultaneously pushing ahead on the commercial front elsewhere. In Canada, Mint Pharmaceuticals broadened its existing distribution partnership with Bayer Inc. to cover several additional products, among them Angeliq, Climara, Triquilar and Xarelto oral suspension. And on the leadership side, Dr. Christoph Koenen stepped into the Chief Medical Officer role on October 1, adding oversight of the pharmaceutical division's medical and scientific strategy to his existing responsibilities heading clinical development and operations.
Should investors sell immediately? Or is it worth buying Bayer?
A $2.2 Billion Bet on American Manufacturing
The longer-term case rests heavily on capacity expansion. Earlier this month, management unveiled a $2.2 billion investment in a new pharmaceutical production site in New Albany, Ohio — a move that signals confidence in the US market even as generic competition intensifies there. The question investors keep circling back to is whether future cash flows will be sufficient to fund both that buildout and the company's ongoing restructuring costs without straining the balance sheet.
Wall Street's near-term expectations, meanwhile, may be running ahead of reality. Richard Vosser, an analyst at JPMorgan, cautioned on October 1 that consensus forecasts for the third quarter could prove too optimistic, largely because of timing effects in the agricultural division. The US bank nonetheless kept its "Overweight" rating and a EUR 61 price target, suggesting it sees little reason to adjust full-year guidance. Bayer has scheduled its Q3 report for November 3, a date that now anchors the calendar for anyone tracking the stock.
Missouri Courtroom and Rising Yields Cloud the Picture
Offsetting the bull case are two persistent overhangs. The first is legal: a fresh Roundup trial opened in a Missouri court in late September, with three plaintiffs alleging that Monsanto, Bayer's subsidiary, failed to adequately test the glyphosate-based herbicide before selling it. The case turns on fundamental questions of product design and safety. Should such proceedings generate new financial liabilities or lengthy settlements, uncertainty could once again dominate the share price.
The second is macroeconomic. Higher bond yields make refinancing corporate debt more expensive and erode the present value of future cash flows — a double squeeze for a company that carries substantial borrowings and is in the middle of a multi-year transformation. Adding to the mix, asset manager Amundi disclosed a threshold notification on voting rights dated September 28, hinting at shifts within the institutional shareholder base.
Whether Bayer can reclaim ground above its 200-day line in short order — and whether the broader rate environment stabilizes — will likely determine if the current weakness proves to be a temporary bout of market nerves or the start of a deeper re-rating. If risk appetite deteriorates further or the Missouri litigation escalates, a test of lower support levels becomes the more probable path. Until November 3, when management must demonstrate how resilient its divisions are against macro headwinds and what financial room the Ohio project leaves, interest-rate developments and courtroom headlines look set to call the tune.
Ad
Bayer Stock: New Analysis - 9 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
